Technology Bundle ID
TAB-2703

Nucleic Acid-based Compositions and Methods for the Species-Specific Detection of Pathogenic Candida Fungi

Linked ID
E-340-2013-0
Lead Inventors
Christine Morrison (CDC)
Co-Inventors
Cheryl Elie (CDC)
Errol Reiss (CDC)
Timonthy Lott (CDC)
Development Stages
Pre-Clinical (in vitro)
Development Status
In vitro data available
ICs
CDC
This invention pertains to the development of oligonucleotides for the rapid nucleic acid-based identification of the Candida fungi species C. haemulonii, C. kefyr, C. lambica, C. lusitaniae, C. norvegensis, C. norvegica, C. rugosa, C. utilis, C. viswanathii, C. zeylanoides, C. dubliniensis, and C. pelliculosa within biological samples. This identification is accomplished by the targeting the internally transcribed spacer-2 (ITS2) region that are specific for each species. The assay is sensitive, specific and rapid. Implementation of the technology will facilitate earlier specific diagnoses, and lead to better antifungal therapy implementation for infected patients.
Commercial Applications
  • Directing antifungal drug therapy for improved patient outcomes
  • Detection, discrimination of Candida species from biological samples
  • Addressing secondary infections of immunosuppressed individuals
Competitive Advantages
  • Easily adapted for use in kits
  • High-throughput capable
  • Rapid and cost-effective

Request More Info

Licensing Contact: